PNNL has developed a decision tool that provides contractors and installers with the information they need to properly select and install cold climate heat pumps, which are a key technology for achieving decarbonization.
A compilation of soil viral genomes provides a comprehensive description of the soil virosphere, its potential to impact global biogeochemistry, and an open database for future investigations of soil viral ecology.
Researchers devised a quantitative and predictive understanding of the cloud chemistry of biomass-burning organic gases helping increase the understanding of wildfires.
PNNL helps deliver efficiency-related rules and requirements that steadily improve performance of America’s buildings, saving energy and costs and reducing carbon emissions.
Spatial proteomics enables researchers to link protein measurements to features in the image of a tissue sample, which are lost using standard approaches.
Mandy Mahoney, director of the DOE Building Technologies Office, visited PNNL in late November. One key agenda item involved meeting with staff for a discussion of effective equity and justice integration in buildings-related research.
Leaders from the DOE Office of Energy Efficiency and Renewable Energy visited PNNL October 19–20 for a firsthand look at capabilities and research progress.
High fidelity simulations enabled by high-performance computing will allow for unprecedented predictive power of molecular level processes that are not amenable to experimental measurement.
PNNL is supporting the floating offshore wind industry to enable gigawatt-scale development of floating offshore wind in the United States while minimizing environmental impacts and supporting local workforces.
Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.
Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.
